Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review

Abstract Background Cognitive impairment are among the core features of schizophrenia, experienced by up to 75% of patients. Available treatment options for schizophrenia including dopamine antagonists and traditional antipsychotic medications have not been shown to confer significant benefits on co...

Full description

Bibliographic Details
Main Authors: Kyle Arsenault‐Mehta, Mario Hochman‐Bérard, Alexander Johnson, Dar'ya Semenova, Bea Nguyen, Jessie Willis, Natalia Mouravska, Ridha Joober, Naista Zhand
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Neuropsychopharmacology Reports
Subjects:
Online Access:https://doi.org/10.1002/npr2.12382